• 1. Natural product isolation
  Otto Sticher Nat. Prod. Rep. 2008 25 517
• 2. Triterpenoids
  J. D. Connolly,R. A. Hill Nat. Prod. Rep. 1995 12 609

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpene saponins

Exploring the Potential of Clinopodiside A (CAS No. 142809-89-0): A Comprehensive Overview

Clinopodiside A (CAS No. 142809-89-0) is a naturally occurring compound that has garnered significant attention in recent years due to its unique chemical structure and potential therapeutic applications. As a member of the saponin family, this compound is derived from the Clinopodium chinense plant, a traditional herb widely used in Chinese medicine. Researchers are increasingly interested in Clinopodiside A for its bioactive properties, which may offer benefits in areas such as inflammation modulation, cardiovascular health, and metabolic regulation.

The molecular structure of Clinopodiside A features a triterpenoid skeleton with sugar moieties attached, a characteristic that contributes to its amphiphilic nature and biological activity. This structural complexity makes 142809-89-0 particularly interesting for drug discovery efforts, as it interacts with various biological targets in ways that synthetic compounds often cannot replicate. Current studies suggest that Clinopodiside A may influence cellular signaling pathways involved in oxidative stress response and immune function.

In the context of modern health trends, Clinopodiside A aligns with growing consumer interest in plant-derived bioactive compounds. Searches for "natural anti-inflammatory agents" and "herbal cardiovascular support" have increased by 35% in the past year, according to recent SEO data. This positions 142809-89-0 as a compound of particular relevance to researchers exploring alternatives to conventional pharmaceuticals. The compound's potential synergy with other plant metabolites is another area attracting scientific attention, especially in the development of nutraceutical formulations.

Analytical characterization of Clinopodiside A reveals several noteworthy physicochemical properties. The compound demonstrates moderate solubility in polar solvents, with stability profiles that make it suitable for various formulation approaches. Recent advances in extraction and purification techniques have improved the availability of high-purity 142809-89-0 for research purposes, addressing one of the previous limitations in studying this compound. These developments coincide with increased market demand for standardized botanical extracts, as evidenced by search trends showing a 42% rise in queries for "standardized herbal compounds" since 2022.

From a pharmacological perspective, preliminary studies indicate that Clinopodiside A may exert its effects through multiple mechanisms. Research suggests potential activity as a modulator of inflammatory cytokines, with particular interest in its effects on TNF-α and IL-6 pathways. These findings have sparked investigations into the compound's possible applications for conditions related to chronic low-grade inflammation, a health concern that has seen a 68% increase in online searches over the past two years. The cardiovascular effects of 142809-89-0 are also under examination, with some studies pointing to vasodilatory and endothelial protective properties.

The safety profile of Clinopodiside A appears favorable based on current toxicological assessments, though comprehensive clinical data remains limited. This safety aspect, combined with its natural origin, makes 142809-89-0 an attractive candidate for further development in the growing market of plant-based therapeutics. Industry analysts note particular interest in such compounds from the nutraceutical sector, where searches for "evidence-based herbal ingredients" have doubled since 2021.

Looking ahead, the research trajectory for Clinopodiside A points toward several promising directions. Current investigations are exploring its potential synergistic effects with other bioactive compounds, its role in metabolic regulation, and possible applications in age-related health support. These research avenues align closely with emerging health trends, including the focus on healthy aging and metabolic flexibility, which have become prominent topics in both scientific literature and consumer health searches. The unique structural features of 142809-89-0 continue to make it a compound of significant interest for both academic researchers and industry professionals seeking to develop novel plant-derived interventions.

As interest in traditional medicine compounds grows globally, Clinopodiside A stands out as a particularly interesting example of how ancient herbal knowledge can intersect with modern scientific investigation. The compound's multifaceted biological activities and favorable safety profile position it as a strong candidate for future therapeutic development. With ongoing research and increasing recognition of its potential, 142809-89-0 may soon transition from being a subject of specialized scientific interest to a more widely recognized bioactive compound with diverse applications in health and wellness.

• 161068-50-4(β-D-Glucopyranoside, (3β,4α,16β)-16,23,28-trihydroxyoleana-11,13(18)-dien-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→4)-O-[β-D-glucopyranosyl-(1→6)]-)
• 115547-32-5(b-D-Galactopyranoside, (3b,16b)-16,28-dihydroxyoleana-11,13(18)-dien-3-yl 2-O-b-D-glucopyranosyl- (9CI))
• 161842-83-7(β-D-Galactopyranoside, (3β,4α,16β)-16,23,28-trihydroxyoleana-11,13(18)-dien-3-yl O-β-D-glucopyranosyl-(1→2)-O-[O-β-D-glucopyranosyl-(1→4)-β-D-glucopyranosyl-(1→3)]-6-deoxy- (9CI))
• 103629-72-7(Prosaikogenin D)
• 110352-77-7(b-D-Glucopyranoside, (3b,16a)-16,28-dihydroxyoleana-11,13(18)-dien-3-yl O-6-deoxy-a-L-mannopyranosyl-(1®4)-O-[b-D-glucopyranosyl-(1®6)]- (9CI))
• 58316-41-9(Saikosaponin B2)
• 58558-08-0(Saikosaponin B1)
• 161842-82-6(b-D-Galactopyranoside, (3b,4a)-23,28-trihydroxyoleana-11,13(18)-dien-3-yl O-b-D-glucopyranosyl-(1®2)-O-[O-b-D-glucopyranosyl-(1®4)-b-D-glucopyranosyl-(1®3)]-6-deoxy- (9CI))
• 141565-05-1(b-D-Galactopyranoside, (3b,4a)-23,28-dihydroxyoleana-11,13(18)-dien-3-yl O-6-deoxy-a-L-mannopyranosyl-(1®4)-O-b-D-glucopyranosyl-(1®3)-O-[b-D-glucopyranosyl-(1®2)]-6-deoxy-)
• 108888-33-1(b-D-Galactopyranoside, (3b,16b)-16,28-dihydroxyoleana-11,13(18)-dien-3-yl (9CI))